Stonegate Updates Coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL) 2Q 2025
Get Alerts IXHL Hot Sheet
Join SI Premium – FREE
DALLAS, TX -- February 18th, 2025 --ย Incannex Healthcare Inc. (NasdaqGM:IXHL):ย Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year. This reduction was primarily due to the completion of the IHL-42X safety and pharmacokinetics clinical trial and the reallocation of resources from the Phase 2 IHL-675A Australia study to a larger U.S. Phase 2 study. The Company recovered 68.3% of these costs with an R&D tax incentive of $0.956 million. The net loss for the quarter was $5.9M, compared to $5.2M in the same period of the previous year.ย
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Incannex secured a strategic financing agreement with Arena Investors, which includes a $50M ELOC with Arena Business Solutions.
- IHL-42X had positive top-line results from a pharmacokinetics(PK) and safety study. The study demonstrated the bioavailability of IHL-42X, confirming the delivery of both drug components.
- When we use a probability adjusted DCF model, it returns an estimated share valuation range ofย $5.08 to $5.96 with a midpoint of $5.50.
Click image above to view full announcement.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
[email protected]
Source: Stonegate, Inc.
Distributed by: Reportable, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CoreAgeRx Announces Advanced NAD+ Protocols for Cellular Energy, Cognitive Support, and Systemic Recovery
- CoreAgeRx Launches Advanced Preventive Longevity Protocols Featuring Microdosing Semaglutide, Microdosing Tirzepatide, and Sermorelin Therapies
- First Trust Portfolios Canada Announces Cap, Buffer and Dates of First Trust Vest U.S. Equity Buffer ETF โ August
Create E-mail Alert Related Categories
Press Releases, ReportableSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share